Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Orucevic, Amila, Bell, John L., McNabb, Alison P., Heidel, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387031/
https://www.ncbi.nlm.nih.gov/pubmed/28243897
http://dx.doi.org/10.1007/s10549-017-4170-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387031/
https://www.ncbi.nlm.nih.gov/pubmed/28243897
http://dx.doi.org/10.1007/s10549-017-4170-3

Ejemplares similares